Lipomer: An Emerging Trends in Nano Science

One of the most sophisticated families of drug deliver methods is liposomal nanomedicine (LNMs), which are therapeutic compounds encapsulated in liposomal nanoparticles (LNs). Several of these LNMs are presently available for purchase, and many more are undergoing clinical testing. Antisense oligonucleotides, small-interfering RNA [siRNA], and plasmid DNA carrying gene therapies are only a few examples of the innovative genetic and conventional medications produced over the last twenty years and their many encapsulation techniques. Among the unique characteristics associated with such LNs are their large (> 6 hours) circulation lifespan, high drug-to-lipid ratio, larg diameter (centered about 100 nm), and remarkable retention of the encapsulated medication. A spherical artificial membrane made of phospholipid bilayers is called a liposome (Fig. 1). Liposomes have drawn a lot of interest as a drug carrier because of their stability, selectivity, biocompatibility, and membrane-like characteristics. Lipomers are spherically-enclosed, lipid-primarily membrane vesicles. Therapeutics abound in lipid nanoparticles, which may or may not have an encapsulated bilayer. Most of those that have received clinical approval have sizes between 50 and 300 nm. Therapeutic proteins have a high selectivity and bio potency and are well-tolerated bioactive molecules employed in various therapeutics. However, they might also exhibit physicochemical instability, impairing therapies by causing a lack of bioactivity. To show how versatile lipid nanoparticles are, this review will give a rundown of their applications in therapeutic protein delivery. The manufacturing method used to create lipid nanoparticles loaded with therapeutic proteins are the subject of particular attention.